Biochemical safety and efficacy of co-administration of Ezetimibe and simvastatin among patients with chronic kidney disease: The second UK-Heart and renal protection (UK-HARP-II) study

Biochemical safety and efficacy of co-administration of Ezetimibe and simvastatin among patients with chronic kidney disease: The second UK-Heart and renal protection (UK-HARP-II) study

Bibliografske podrobnosti
Main Authors:	Landray, M, Baigent, C, Leaper, C
Format:	Conference item
Izdano:	2003

Podobne knjige/članki

The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD.
od: Landray, M, et al.
Izdano: (2006)

First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease.
od: Baigent, C, et al.
Izdano: (2005)

Efficacy and safety of simvastatin and safety of low-dose aspirin among patients with chronic kidney disease: Final results of the first UK-Heart and Renal Protection (UK-HARP-1) study.
od: Baigent, C, et al.
Izdano: (2002)

Ezetimibe/simvastatin (vytorin) in heart and renal protection: The SHARP trial
od: Alexander, W, et al.
Izdano: (2011)

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
od: Baigent, C, et al.
Izdano: (2011)

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
od: Baigent, C, et al.
Izdano: (2011)

Ezetimibe/simvastatin vs simvastatin in coronary heart disease patients with or without diabetes
od: Hanson Mary E, et al.
Izdano: (2010-07-01)

Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: UK Heart and Renal Protection (UK HARP)-III. Rationale, trial design and baseline data
od: Haynes, R, et al.
Izdano: (2016)

Simultaneous Determination of Simvastatin and Ezetimibe in Tablets by HPLC
od: D. Anantha Kumar, et al.
Izdano: (2009-01-01)

Cost-effectiveness of lowering LDL cholesterol with statins and ezetimibe in chronic kidney disease
od: Mihaylova, B, et al.
Izdano: (2019)

Ezetimibe and simvastatin for the prevention of cardiovascular events in predialysis chronic kidney disease patients: a review
od: Naderi S, et al.
Izdano: (2012-12-01)

Simultaneous HPTLC Estimation of Simvastatin and Ezetimibe in Tablet Dosage Form
od: Bhupendra Shrestha, et al.
Izdano: (2010-01-01)

Analyses of cancer data from three ezetimibe trials.
od: Peto, R, et al.
Izdano: (2008)

Simultaneous inhibition of cholesterol absorption and synthesis in combined therapy with ezetimibe and simvastatin
od: D. M. Aronov
Izdano: (2005-08-01)

A report of successful management with simvastatin plus ezetimibe in alopecia areata
od: Javier Arellano, et al.
Izdano: (2020-11-01)

Simvastatin and Ezetimibe-Loaded Nanofibers Administered Locally to Augment Bone Healing
od: Shayan Amiri, et al.
Izdano: (2021-01-01)

Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and/or simvastatin in men
od: Thomas Sudhop, et al.
Izdano: (2009-10-01)

Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin
od: Farnier Michel, et al.
Izdano: (2011-11-01)

Synergistic effect of simvastatin and ezetimibe on lipid and pro-inflammatory profiles in pre-diabetic subjects
od: Kater Ana-Lucia A, et al.
Izdano: (2010-06-01)

Development and Validation of a Derivative Spectrophotometric Method for Simultaneous Determination of Simvastatin and Ezetimibe
od: Effat Souri, et al.
Izdano: (2010-01-01)

Preformulation Studies of Ezetimibe-Simvastatin Solid Dispersions in the Development of Fixed-Dose Combinations
od: Agata Górniak, et al.
Izdano: (2022-04-01)

Simvastatin to reduce pulmonary dysfunction in patients with acute respiratory distress syndrome: the HARP-2 RCT
od: Daniel F McAuley, et al.
Izdano: (2018-01-01)

Ezetimibe + simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study)
od: Le Grazie Cristina, et al.
Izdano: (2010-05-01)

13. THE LONG-TERM EFFECT BETWEEN CO-ADMINISTRATION OF SIMVASTATIN AND EZETIMIBE AND ATORVASTATIN ON CENTRAL PULSE WAVE VELOCITY IN ADULTS WITH HYPERCHOLESTEROLEMIA
od: Young Soo Lee, et al.
Izdano: (2009-10-01)

Microemulsion Liquid Chromatographic Method for Simultaneous Determination of Simvastatin and Ezetimibe in Their Combined Dosage Forms
od: Mohammed E. A. Hammouda, et al.
Izdano: (2013-01-01)

The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatins⃞
od: Dawn E. Telford, et al.
Izdano: (2007-03-01)

Evidence from a randomized trial that simvastatin, but not ezetimibe, upregulates circulating PCSK9 levels.
od: Heiner K Berthold, et al.
Izdano: (2013-01-01)

VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrate
od: Michel Farnier, et al.
Izdano: (2008-12-01)

Ezetimibe in Combination With Simvastatin Reduces Remnant Cholesterol Without Affecting Biliary Lipid Concentrations in Gallstone Patients
od: Osman Ahmed, et al.
Izdano: (2018-12-01)

The harp lesson /
od: 262936 Tennant, Emma
Izdano: (2005)

HARP Syndrome
od: J Gordon Millichap
Izdano: (1992-02-01)

Harp Syndrome
od: J Gordon Millichap
Izdano: (1995-04-01)

Renal function: an emerging risk factor for cardiovascular disease?
od: Landray, M, et al.
Izdano: (2001)

Co-Amorphous Formation of Simvastatin-Ezetimibe: Enhanced Physical Stability, Bioavailability and Cholesterol-Lowering Effects in LDLr−/−Mice
od: Shamuha Bahetibieke, et al.
Izdano: (2022-06-01)

Effects of ezetimibe/simvastatin 10/10 mg versus Rosuvastatin 10 mg on carotid atherosclerotic plaque inflammation
od: Minyoung Oh, et al.
Izdano: (2019-08-01)

High Dose Atorvastatin Associated with Increased Risk of Significant Hepatotoxicity in Comparison to Simvastatin in UK GPRD Cohort.
od: Alan T Clarke, et al.
Izdano: (2016-01-01)

Which cardiovascular risk factors matter in chronic kidney disease?
od: Baigent, C, et al.
Izdano: (2007)

09.01 EZETIMIBE AND SIMVASTATIN BOTH REDUCE INFLAMMATION, DISEASE ACTIVITY, AORTIC STIFFNESS AND IMPROVE ENDOTHELIAL FUNCTION IN RHEUMATOID ARTHRITIS
od: K.M. Maki-Petaja*, et al.
Izdano: (2007-06-01)

EXPERT CONSENSUS. ROLE OF COMBINATION LIPID-LOWERING THERAPY (SIMVASTATIN/EZETIMIBE 20/10 MG) IN THE CORRECTION OF LIPID METABOLISM DISTURBANCES IN PATIENTS WITH CHRONIC KIDNEY DISEASE
od: A. Catapano, et al.
Izdano: (2013-08-01)

Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP)
od: Herrington, WG, et al.
Izdano: (2023)